Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy

Cancer Biology and Therapy

Volumn 15, Issue 12, 2014, Pages 1635-1645

  Sun, Qiaoling ^a   Zhou, Jinghong ^a   Zhang, Zheng ^a   Guo, Mingchuan ^a   Liang, Junqing ^a   Zhou, Feng ^a   Long, Jingwen ^a   Zhang, Wei ^a   Yin, Fang ^a   Cai, Huaqing ^a   Yang, Haibin ^a   Zhang, Weihan ^a   Gu, Yi ^a   Ni, Liang ^a   Sai, Yang ^a   Cui, Yumin ^a   Zhang, Meifang ^a   Hong, Minhua ^a   Sun, Junen ^a   Yang, Zheng ^a   Qing, Weiguo ^a   Su, Weiguo ^a   Ren, Yongxin ^a   more..

^a Hutchison MediPharma Limited   (China)

Author keywords

Angiogenesis; Anti tumor activity; Cancer treatment; Fruquintinib; Tumor xenograft models; Tyrosine kinase inhibitor; VEGFR 1 2 3

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; FRUQUINTINIB; OXALIPLATIN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANGIOGENESIS INHIBITOR; BENZOFURAN DERIVATIVE; HMPL-013; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; EMBRYO; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG PARENCHYMA; MAXIMUM PLASMA CONCENTRATION; MICROTUBULE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; EPITHELIUM CELL; IC50; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOFURANS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MICE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SIGNAL TRANSDUCTION; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920116720     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/15384047.2014.964087     Document Type: Article

References (38)

1. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000; 19:5598-605; PMID:11114740; http://dx.doi.org/10.1038/sj. onc.1203855
2. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-10; PMID:12778130; http://dx.doi.org/10.1038/ nrc1093
3. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468:824-8; PMID:21102434; http://dx.doi.org/ 10.1038/nature09557
4. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-49; PMID:18463380; http://dx.doi.org/ 10.1056/NEJMra0706596
5. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368-80; PMID:12409337; http:// dx.doi.org/10.1200/JCO.2002.10.088
6. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55:4575-80; PMID:7553632
7. Farhang Ghahremani M, Goossens S, Nittner D, Bisteau X, Bartunkova S, Zwolinska A, Hulpiau P, Haigh K, Haenebalcke L, Drogat B, et al. p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway. Cell Death Differ 2013; 20:888-97; PMID:23449391; http://dx.doi.org/ 10.1038/cdd.2013.12
8. Raja R, Kale S, Thorat D, Soundararajan G, Lohite K, Mane A, Karnik S, Kundu GC. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1a-mediated VEGF-dependent angiogenesis. Oncogene 2014; 33:2053-64; PMID: 23728336; http://dx.doi.org/10.1038/onc.2013.171
9. Chatterjee S, Heukamp LC, Siobal M, Schöttle J, Wieczorek C, Peifer M, Frasca D, Koker M, König K, Meder L, et al. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest 2013; 123:1732-40; PMID:23454747; http://dx.doi.org/10.1172/JCI65385
10. Wang X, Chen X, Fang J, Yang C. Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth. Int J Clin Exp Pathol 2013; 6:586-97; PMID:23573305
11. Martins SF, Garcia EA, Luz MA, Pardal F, Rodrigues M, Filho AL. Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, KDR and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics 2013; 10:55-67; PMID:23603341
12. Pan L, Baek S, Edmonds PR, Roach M, Wolkov H, Shah S, Pollack A, Hammond ME, Dicker AP. Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610. Radiat Oncol 2013; 8:100; PMID:23618468; http:// dx.doi.org/10.1186/1748-717X-8-100
13. Engels K, du Bois A, Harter P, Fisseler-Eckhoff A, Kommoss F, Stauber R, Kaufmann M, Nekljudova V, Loibl S. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection. J Clin Pathol 2009; 62:448-54; PMID:19126566; http://dx.doi.org/ 10.1136/jcp.2008.063859
14. Simonetti O, Lucarini G, Rubini C, Goteri G, Zizzi A, Staibano S, Campanati A,GanzettiG,Di Primio R,Offidani A. Microvessel density and VEGF, HIF-1a expression in primary oral melanoma: correlation with prognosis. Oral Dis 2013; 19:620-7; PMID:23279259; http://dx.doi.org/10.1111/odi.12048
15. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of bloodislandformation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376:62-6; PMID:7596435; http:// dx.doi.org/10.1038/376062a0
16. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011; 2:1097-105; PMID:22866201; http://dx.doi.org/10.1177/1947601911423031
17. Ziche M, Donnini S, Morbidelli L. Development of new drugs in angiogenesis. Curr Drug Targets 2004; 5:485-93; PMID:15216914; http://dx.doi.org/ 10.2174/1389450043345371
18. Zhou CC, Bai CX, Guan ZZ, Jiang GL, Shi YK, Wang MZ, Wu YL, Zhang YP, Zhu YZ. Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study. Clin Transl Oncol 2014; 16:463-8; PMID:24002945; http://dx.doi.org/10.1007/s12094-013-1102-5
19. Ciuleanu T, Tsai CM, Tsao CJ, Milanowski J, Amoroso D, Heo DS, Groen HJ, Szczesna A, Chung CY, Chao TY, et al. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer 2013; 82:276-81; PMID:23992877; http://dx.doi.org/ 10.1016/j.lungcan.2013.08.002
20. El-Rayes BF, Zalupski M, Bekai-Saab T, Heilbrun LK, Hammad N, Patel B, Urba S, Shields AF, Vaishampayan U, Dawson S, et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010; 21:1999-2004; PMID:20332133; http://dx.doi. org/10.1093/annonc/mdq065
21. MoehlerM, Sprinzl MF, Abdelfattah M, SchimanskiCC, Adami B, Godderz W, Majer K, Flieger D, Teufel A, Siebler J, et al.Capecitabine and Irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 2009; 15:449-56; PMID: 19152449; http://dx.doi.org/10.3748/wjg.15.449
22. Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 2007; 27:1125-44; PMID:17655513; http://dx.doi.org/10.1592/phco.27.8.1125
23. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69:223-40; PMID:19228077; http://dx.doi.org/ 10.2165/00003495-200969020-00006
24. Sartore-Bianchi A, Zeppellini A, Amatu A, Ricotta R, Bencardino K, Siena S. Regorafenib in metastatic colorectal cancer. Expert Rev Anticancer Ther 2014; 14:255-65; PMID:24559322; http://dx.doi.org/ 10.1586/14737140.2014.894887
25. van Geel RM, Beijnen JH, Schellens JH. Concise drug review: pazopanib and axitinib. Oncologist 2012; 17:1081-9; PMID:22733795; http://dx.doi.org/ 10.1634/theoncologist.2012-0055
26. Gu Y, Wang J, Li K, Zhang L, Ren HC, Guo LX, Sai Y, Zhang WH, Su WG. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. Cancer Chemoth Pharmacol 2014; 74:95-115; PMID:24817647; http://dx.doi.org/ 10.1007/s00280-014-2471-3
27. Huang L, Huang Z, Bai Z, Xie R, Sun L, Lin K. Development and strategies of KDR/KDR inhibitors. Future Med Chem 2012; 4:1839-52; PMID:23043480; http://dx.doi.org/10.4155/fmc.12.121
28. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull 2011; 34:1785-8; PMID:22130231; http://dx.doi.org/ 10.1248/bpb.34.1785
29. Koch S, Tugues S, Li X, Gualandi L, laesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011; 437:169-83; PMID: 21711246; http://dx.doi.org/10.1042/BJ20110301
30. Witzenbichler B, Asahara T, Murohara T, Silver M, Spyridopoulos I, Magner M, Principe N, Kearney M, Hu JS, Isner JM. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 1998; 153:381-94; PMID:9708799; http://dx.doi.org/10.1016/S0002-9440(10)65582-4
31. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000; 19:5598-605; PMID:11114740; http://dx.doi.org/10.1038/sj. onc.1203855
32. Huang YW, Xu LQ, Luo RZ,Huang X, Hou T, Zhang YN. VEGF-c expression in an in vivo model of orthotopic endometrial cancer and retroperitoneal lymph node metastasis. Reprod Biol Endocrinol 2013; 11:49; PMID:23693075; http://dx.doi.org/10.1186/1477-7827-11-49
33. Kigure W, Fujii T, Sutoh T, Morita H, Katoh T, Yajima RN, Yamaguchi S, Tsutsumi S, Asao T, Kuwano H. The association of VEGF-C expression with tumor lymphatic vessel density and lymph node metastasis in patients with gastric cancer and gastrointestinal stromal tumor. Hepatogastroenterology 2013; 60:277-80; PMID:23574654
34. Yao G, He P, Chen L, Hu X, Gu F, Ye C. MT1-MMP in breast cancer: induction of VEGF-C correlates with metastasis and poor prognosis. Cancer Cell Int 2013; 13:98; PMID:24119788; http://dx.doi.org/10.1186/ 1475-2867-13-98
35. Wong SY, Haack H, Crowley D, Barry M, Bronson RT, Hynes RO. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res 2005; 65:9789-98; PMID:16267000; http://dx.doi.org/10.1158/ 0008-5472.CAN-05-0901
36. Martins SF, Garcia EA, Luz MA, Pardal F, Rodrigues M, Filho AL. Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics 2013; 10:55-67; PMID:23603341
37. Al-Rawi MA, Jiang WG. Lymphangiogenesis and cancer metastasis. Front Biosci 2011; 16:23-39; http://dx. doi.org/10.2741/3715
38. th annual meeting of the American association for cancer research. 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73 (8 Suppl): Abstract nr 2413. doi:10.1158/1538-7445.AM2013-2413